GlassScriptPhysician profile
Angela K Curry
NPI 1205806536
$1,935.42
in general payments reported to CMS, 2019-2025
22 companies · $43.05 in 2025
The $43.05 reported for 2025 was less than what a typical Gynecology provider received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $189 · 2020: $58.79 · 2021: $372 · 2022: $335 · 2023: $825 · 2024: $112 · 2025: $43.05.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $493 · Travel and Lodging: $488.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $492.78 |
| Travel and Lodging | $487.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Applied Medical Resources Corporation | $502.41 | 2023 | Gelpoint V-Path |
| Abbvie INC. | $490.99 | 2019-2024 | Orilissa, Lo Loestrin Fe |
| Mayne Pharma Commercial LLC | $153.65 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $145.25 | 2022-2025 | |
| Exeltis, USA INC. | $69.59 | 2021-2023 | Slynd |
| Pfizer INC. | $55.79 | 2019-2024 | |
| Therapeuticsmd, INC. | $53.88 | 2019-2022 | |
| Aspira Women'S Health INC | $51.98 | 2022 | |
| Amag Pharmaceuticals, INC. | $51.43 | 2019 | |
| Hologic Sales and Service, LLC | $43.73 | 2021-2025 | Aptima, Thinprep 2000 Processor |
| Merck Sharp & Dohme LLC | $43.06 | 2019-2022 | |
| Avion Pharmaceuticals | $41.17 | 2021-2022 | |
| Currax Pharmaceuticals LLC | $37.61 | 2021-2022 | |
| Scynexis, INC. | $32.95 | 2022 | |
| Mycovia Pharmaceuticals, INC. | $29.43 | 2023 | Vivjoa |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $29.40 | 2023 | Veozah |
| Agile Therapeutics, INC. | $22.85 | 2023 | Twirla |
| Shield Therapeutics INC | $21.28 | 2024 | |
| Mylan Pharmaceuticals INC. | $17.35 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.72 | 2019 | |
| Millicent US INC | $13.68 | 2021 | |
| Idorsia Pharmaceuticals US INC | $12.22 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Curry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.